S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Is Buying an Aged Corporation a Good Idea?
Is This The End of Capitalism? (Ad)
MarketBeat Week in Review – 1/23- 1/27
Visa, L3Harris rise; Intel, Eastman Chemical fall
Is This The End of Capitalism? (Ad)
How major US stock indexes fared Friday 1/27/2023
Wall Street adds more to its big January after strong week
Is This The End of Capitalism? (Ad)
Italy's premier visits Libya for talks on energy, migration
Japan firm opens whale meat vending machines to push sales
S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Is Buying an Aged Corporation a Good Idea?
Is This The End of Capitalism? (Ad)
MarketBeat Week in Review – 1/23- 1/27
Visa, L3Harris rise; Intel, Eastman Chemical fall
Is This The End of Capitalism? (Ad)
How major US stock indexes fared Friday 1/27/2023
Wall Street adds more to its big January after strong week
Is This The End of Capitalism? (Ad)
Italy's premier visits Libya for talks on energy, migration
Japan firm opens whale meat vending machines to push sales
S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Is Buying an Aged Corporation a Good Idea?
Is This The End of Capitalism? (Ad)
MarketBeat Week in Review – 1/23- 1/27
Visa, L3Harris rise; Intel, Eastman Chemical fall
Is This The End of Capitalism? (Ad)
How major US stock indexes fared Friday 1/27/2023
Wall Street adds more to its big January after strong week
Is This The End of Capitalism? (Ad)
Italy's premier visits Libya for talks on energy, migration
Japan firm opens whale meat vending machines to push sales
S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Is Buying an Aged Corporation a Good Idea?
Is This The End of Capitalism? (Ad)
MarketBeat Week in Review – 1/23- 1/27
Visa, L3Harris rise; Intel, Eastman Chemical fall
Is This The End of Capitalism? (Ad)
How major US stock indexes fared Friday 1/27/2023
Wall Street adds more to its big January after strong week
Is This The End of Capitalism? (Ad)
Italy's premier visits Libya for talks on energy, migration
Japan firm opens whale meat vending machines to push sales
NASDAQ:SGEN

Seagen - SGEN Stock Forecast, Price & News

$140.67
+0.98 (+0.70%)
(As of 01/27/2023 12:00 AM ET)
Add
Compare
Today's Range
$138.82
$141.02
50-Day Range
$117.37
$140.67
52-Week Range
$105.43
$183.00
Volume
869,706 shs
Average Volume
876,566 shs
Market Capitalization
$26.12 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$161.21

Seagen MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.75 Rating Score
Upside/​Downside
14.6% Upside
$161.21 Price Target
Short Interest
Healthy
1.62% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.96
Upright™ Environmental Score
News Sentiment
0.01mentions of Seagen in the last 14 days
Based on 13 Articles This Week
Insider Trading
Selling Shares
$7.28 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($3.54) to ($2.30) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.44 out of 5 stars

Medical Sector

195th out of 1,055 stocks

Biological Products, Except Diagnostic Industry

36th out of 170 stocks


SGEN stock logo

About Seagen (NASDAQ:SGEN) Stock

Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment of advanced or metastatic urothelial cancer; and TUKYSA, an oral small molecule tyrosine kinase inhibitor for the treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer. It also develops TIVDAK for metastatic cervical cancer and other solid tumors; Ladiratuzumab Vedotin, an ADC targeting LIV-1 for metastatic breast cancer and solid tumors; Disitamab Vedotin, a novel HER2-targeted ADC; and SEA-CD40, SEA-TGT, SEA-BCMA, and SEA-CD70 for various cancer diseases. Seagen Inc. has collaboration agreements with Takeda Pharmaceutical Company Limited; Agensys, Inc.; Genmab A/S; Merck; and RemeGen, Co. Ltd. The company was formerly known as Seattle Genetics, Inc. and changed its name to Seagen Inc. in October 2020. Seagen Inc. was incorporated in 1997 and is headquartered in Bothell, Washington.

Receive SGEN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Seagen and its competitors with MarketBeat's FREE daily newsletter.

SGEN Stock News Headlines

Seagen Inc. (NASDAQ:SGEN) CMO Roger D. Dansey Sells 10,000 Shares
Seagen Inc. (NASDAQ:SGEN) Insider Jean I. Liu Sells 5,000 Shares
The Next Big Crisis Is Here
You just can’t see it yet because it’s NOT a banking, financial, or economic crisis… it’s far worse and threatens every dollar in your retirement account.
Morgan Stanley Cuts Seagen (NASDAQ:SGEN) Price Target to $170.00
Seagen (NASDAQ:SGEN) PT Lowered to $170.00 at Berenberg Bank
SVB Leerink Boosts Seagen (NASDAQ:SGEN) Price Target to $162.00
Seagen Inc. (NASDAQ:SGEN) Insider Jean I. Liu Sells 578 Shares
Is This The End of Capitalism?
EXPOSED: The establishment plot to disenfranchise and impoverish millions of Americans…
Seagen Inc. (SGEN) Q3 2022 Earnings Call Transcript
Seagen Reports Third Quarter 2022 Financial Results
A Bearish Sign Appears On Seagen's Chart
See More Headlines
Receive SGEN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Seagen and its competitors with MarketBeat's FREE daily newsletter.

SGEN Company Calendar

Last Earnings
10/28/2021
Today
1/28/2023
Next Earnings (Confirmed)
2/15/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:SGEN
CUSIP
81257810
Employees
2,675
Year Founded
1998

Price Target and Rating

Average Stock Price Forecast
$161.21
High Stock Price Forecast
$188.00
Low Stock Price Forecast
$135.00
Forecasted Upside/Downside
+14.6%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.75
Research Coverage
16 Analysts

Profitability

Net Income
$-674,470,000.00
Pretax Margin
-34.09%

Debt

Sales & Book Value

Annual Sales
$1.57 billion
Book Value
$16.76 per share

Miscellaneous

Free Float
134,978,000
Market Cap
$26.12 billion
Optionable
Optionable
Beta
0.55

Social Links


Key Executives

  • Mr. Todd E. SimpsonMr. Todd E. Simpson (Age 62)
    Chief Financial Officer
    Comp: $1.17M
  • Ms. Jean I.  Liu J.D.Ms. Jean I. Liu J.D. (Age 55)
    M.S., Chief Legal Officer
    Comp: $1.11M
  • Mr. Charles R. RompMr. Charles R. Romp (Age 55)
    Exec. VP of Commercial U.S.
    Comp: $1.02M
  • Dr. Roger D. Dansey M.D.Dr. Roger D. Dansey M.D. (Age 67)
    Pres of R&D
    Comp: $1.53M
  • Mr. David R. Epstein B.Sc. (Age 61)
    M.B.A., CEO & Director
  • Dr. Vaughn B. Himes Ph.D. (Age 62)
    Chief Technical Officer
  • Peggy Pinkston
    Sr. VP of Investor Relations
  • Mr. David Caouette
    VP of Corp. Communications
  • Mr. Matt Skelton
    VP of Marketing
  • Mr. Christopher P. Pawlowicz
    Exec. VP of HR













SGEN Stock - Frequently Asked Questions

Should I buy or sell Seagen stock right now?

16 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Seagen in the last year. There are currently 4 hold ratings and 12 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" SGEN shares.
View SGEN analyst ratings
or view top-rated stocks.

What is Seagen's stock price forecast for 2023?

16 brokerages have issued 1-year target prices for Seagen's shares. Their SGEN share price forecasts range from $135.00 to $188.00. On average, they anticipate the company's stock price to reach $161.21 in the next year. This suggests a possible upside of 14.6% from the stock's current price.
View analysts price targets for SGEN
or view top-rated stocks among Wall Street analysts.

How have SGEN shares performed in 2023?

Seagen's stock was trading at $128.51 at the start of the year. Since then, SGEN shares have increased by 9.5% and is now trading at $140.67.
View the best growth stocks for 2023 here
.

Are investors shorting Seagen?

Seagen saw a increase in short interest in the month of January. As of January 15th, there was short interest totaling 3,000,000 shares, an increase of 15.4% from the December 31st total of 2,600,000 shares. Based on an average daily volume of 982,200 shares, the short-interest ratio is currently 3.1 days.
View Seagen's Short Interest
.

When is Seagen's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, February 15th 2023.
View our SGEN earnings forecast
.

How can I listen to Seagen's earnings call?

Seagen will be holding an earnings conference call on Wednesday, February 15th at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link.

How were Seagen's earnings last quarter?

Seagen Inc. (NASDAQ:SGEN) announced its quarterly earnings data on Thursday, October, 28th. The biotechnology company reported ($1.61) earnings per share for the quarter, missing analysts' consensus estimates of ($0.56) by $1.05. The biotechnology company had revenue of $424.60 million for the quarter, compared to analyst estimates of $384.83 million. Seagen had a negative trailing twelve-month return on equity of 21.56% and a negative net margin of 34.16%. The company's quarterly revenue was down 60.0% compared to the same quarter last year. During the same period in the prior year, the firm earned $3.50 EPS.

What guidance has Seagen issued on next quarter's earnings?

Seagen issued an update on its FY 2022 earnings guidance on Thursday, November, 3rd. The company provided EPS guidance of for the period. The company issued revenue guidance of $1.82 billion-$1.86 billion, compared to the consensus revenue estimate of $1.84 billion.

What is Clay B. Siegall's approval rating as Seagen's CEO?

107 employees have rated Seagen Chief Executive Officer Clay B. Siegall on Glassdoor.com. Clay B. Siegall has an approval rating of 99% among the company's employees. This puts Clay B. Siegall in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Seagen own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Seagen investors own include NVIDIA (NVDA), AbbVie (ABBV), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Salesforce (CRM), QUALCOMM (QCOM), Tesla (TSLA), Micron Technology (MU), Netflix (NFLX) and Alibaba Group (BABA).

What is Seagen's stock symbol?

Seagen trades on the NASDAQ under the ticker symbol "SGEN."

Who are Seagen's major shareholders?

Seagen's stock is owned by a variety of institutional and retail investors. Top institutional investors include Manning & Napier Group LLC (0.19%), Pinnacle Associates Ltd. (0.13%), National Bank of Canada FI (0.10%), Allspring Global Investments Holdings LLC (0.07%), Gateway Investment Advisers LLC (0.01%) and DNB Asset Management AS (0.01%). Insiders that own company stock include Bros Advisors Lp Baker, Charles R Romp, Charles R Romp, Clay B Siegall, Clay B Siegall, Daniel G Welch, Daniel G Welch, David W Gryska, David W Gryska, Jean I Liu, Jean I Liu, Marc E Lippman, Morgan E Obrien, Roger D Dansey, Roger D Dansey, Todd E Simpson, Todd E Simpson, Vaughn B Himes and Vaughn B Himes.
View institutional ownership trends
.

How do I buy shares of Seagen?

Shares of SGEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Seagen's stock price today?

One share of SGEN stock can currently be purchased for approximately $140.67.

How much money does Seagen make?

Seagen (NASDAQ:SGEN) has a market capitalization of $26.12 billion and generates $1.57 billion in revenue each year. The biotechnology company earns $-674,470,000.00 in net income (profit) each year or ($3.45) on an earnings per share basis.

How many employees does Seagen have?

The company employs 2,675 workers across the globe.

Does Seagen have any subsidiaries?
The following companies are subsidiares of Seagen: Cascadian Therapeutics.
Read More
How can I contact Seagen?

Seagen's mailing address is 21823 30TH DRIVE SE SUITE, BOTHELL WA, 98021. The official website for the company is www.seattlegenetics.com. The biotechnology company can be reached via phone at (425) 527-4000, via email at investors@seagen.com, or via fax at 425-527-4001.

This page (NASDAQ:SGEN) was last updated on 1/28/2023 by MarketBeat.com Staff